Entrada's Duchenne pair faces 2027 data tests with funding mapped into late 2027

Entrada Therapeutics has tied its near-term value to two data readouts in 2027, and says it has the money to reach both. Presenting third-quarter 2026 results on 5 November, the company reported $193.0m in cash at 30 September and said this funds operations into the fourth quarter of 2027.

The two readouts come from its Duchenne muscular dystrophy programmes, ENTR-601-44 and ENTR-601-45. Cohort 2 data from ELEVATE-44-201 are expected in the first quarter of 2027, and Cohort 2 data from ELEVATE-45-201 in the first half of 2027. On the company's stated timelines, both fall inside the runway it has described.

Entrada also said Cohort 1 of ELEVATE-45-201 met its safety and tolerability objective. The material available to CompePharma did not include detailed trial data, so efficacy results and specific safety figures cannot be reported here.

Separately, the US Food and Drug Administration's Office of Orphan Products Development granted orphan drug designation to ENTR-601-45. By way of general context, such designations are for products aimed at rare diseases and can carry development incentives. They are not marketing authorisations and say nothing about the outcome of any future regulatory review.